Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy

Epilepsy Behav. 2011 Apr;20(4):691-3. doi: 10.1016/j.yebeh.2011.02.005. Epub 2011 Mar 15.


The results of adjunctive lacosamide treatment in 18 pediatric patients with pharmacoresistant focal epilepsy are reported. All had severe forms of focal epilepsy with or without secondary generalization and were concurrently receiving one to three other antiepileptic drugs. Lacosamide was administered orally, and final dose, after slow titration, ranged between 1.7 and 10 mg/kg. Mean treatment duration was 8 months (range=3 weeks-17 months). Treatment efficacy was assessed at two time points with a 1-year interval. The reported greater than 50% reduction in seizure frequency was 36% in the initial short-term and 20% in the following long-term assessment. Side effects, mostly somnolence and irritability, were reported by 39% of patients in both evaluations. Our data suggest that lacosamide treatment in pediatric patients is safe at doses up to 10 mg/kg/day without any major side effects, but studies in larger series are needed to validate and extend these findings.

MeSH terms

  • Acetamides / administration & dosage*
  • Administration, Oral
  • Adolescent
  • Anticonvulsants / administration & dosage*
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Epilepsies, Partial / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Lacosamide
  • Male
  • Pediatrics
  • Treatment Outcome


  • Acetamides
  • Anticonvulsants
  • Lacosamide